Volume | 136,907 |
|
|||||
News | - | ||||||
Day High | 0.179935 | Low High |
|||||
Day Low | 0.15884 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
IntelGenx Technologies Corporation (QB) | IGXT | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.178 | 0.15884 | 0.179935 | 0.1785 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
31 | 136,907 | $ 0.176219 | $ 24,126 | - | 0.09 - 0.223725 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
15:59:57 | 100 | $ 0.1619 | USD |
IntelGenx Technologies Corporation (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
41.92M | 174.66M | 124.54M | 1.04M | -9.93M | -0.06 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
IntelGenx Technologies (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IGXT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.1675 | 0.18 | 0.14644 | 0.1656615 | 178,971 | -0.0056 | -3.34% |
1 Month | 0.19 | 0.19 | 0.13955 | 0.1678732 | 130,313 | -0.0281 | -14.79% |
3 Months | 0.1363 | 0.19 | 0.131 | 0.1654507 | 101,589 | 0.0256 | 18.78% |
6 Months | 0.15 | 0.199 | 0.102 | 0.1541006 | 97,726 | 0.0119 | 7.93% |
1 Year | 0.1461 | 0.223725 | 0.09 | 0.1535885 | 89,681 | 0.0158 | 10.81% |
3 Years | 0.668 | 0.7104 | 0.09 | 0.3059483 | 136,333 | -0.5061 | -75.76% |
5 Years | 0.56 | 0.7104 | 0.09 | 0.311859 | 199,215 | -0.3981 | -71.09% |
IntelGenx Technologies (QB) Description
IntelGenx Corp. is a drug delivery company established in 2003 and headquartered in Montreal, Quebec, Canada. Our focus is on the development and manufacturing of novel oral thin film products for the pharmaceutical market. More recently, we have made the strategic decision to enter the Canadian cannabis market with a non-prescription cannabis infused oral film expected to be launched in 2021 and in 2020 we made the decision to enter the psychedelic market. In addition, we are offering partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical research and development ("R&D"), clinical monitoring, regulatory support, tech transfer, manufacturing scale-up and commercial manufacturing. IntelGenx Corp. is the directly and indirectly fully owned Canadian operating company of IntelGenx Technologies Corp. The US parent IntelGenx Technologies Corp. is listed on the TSX and OTC-QB. For more information, visit www.intelgenx.com |